$26.04
-0.18 (-0.69%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TYRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 9 tracked-famous managers (MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, MILLENNIUM MANAGEMENT LLC, +4 more) · FINRA short interest 17.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaNCT07265947To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg, Dabogratinib (TYRA-300) TBD | Low Grade Upper Tract Urothelial Carcinoma | 230 | Oct 2030 | ≤ 1,534 d | 2026-08-03 |
| A Study of TYRA-300 in Children With Achondroplasia: BEACH301NCT06842355Incidence of treatment-related adverse events as assessed by CTCAE v5.0Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg, TYRA-300 0.50 mg/kg | Achondroplasia | 92 | Jan 2030 | ≤ 1,261 d | 2026-07-31 |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerNCT06995677To assess the efficacy of TYRA-300 in LG IR-NMIBC participantsRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose TBD | Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions | 90 | Feb 2028 | ≤ 559 d | 2026-08-06 |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsNCT06915753Maximum tolerated dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: TYRA-430 | Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma | 100 | Jan 2028 | ≤ 530 d | 2026-07-29 |
| Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsNCT05544552Phase 1 Part A: To determine the maximum tolerated doses (MTD).Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: TYRA-300 | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma | 310 | Nov 2026 | ≤ 103 d | 2026-01-12 |
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsNCT06160752Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200.Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma | 40 | Sep 2026 | ≤ 42 d | 2026-08-05 |
| A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult ParticipantsNCT06006702Pharmacokinetics single-dose CmaxRandomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: TYRA-300-B01 | Healthy | 60 | May 2025 | — | 2025-03-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19